Dermatology· Topic 3.4 Disorders of hair, nails, and pilosebaceous units· 3.4.7

Psoriasis

Psoriasis is a chronic, relapsing, immune-mediated dermatosis of accelerated keratinocyte turnover, classically presenting as sharply demarcated, silvery-scaled plaques on extensor surfaces, with guttate, inverse, pustular, and erythrodermic variants and an associated psoriatic arthritis. Mild-to-moderate disease is treated with emollients and topical corticosteroids with or without a vitamin-D analogue (calcipotriene 0.005% twice daily), while widespread (over 10% body surface area), recalcitrant, or severe disease escalates to phototherapy, methotrexate (weekly single dose 7.5 to 25 mg), or a biologic such as adalimumab, ustekinumab, or secukinumab, never a systemic glucocorticoid.

11 min read3 practice questions8 key factsSubscriber article
  • Topic review
    The full article, organized the way the exam asks it.
  • ABIM-format MCQs
    Vignettes with an explanation for every wrong answer.
  • Key facts
    The numbers and thresholds worth memorizing, up front.
  • AI tutor
    MedBrain answers the question you're stuck on.

What this article covers

  • Overview

    Definition: psoriasis is a chronic, relapsing, immune-mediated dermatosis driven by keratinocyte hyperproliferation, producing sharply demarcated erythematous plaques with silvery-white scale.

  • Epidemiology

    Common: psoriasis affects approximately 2 to 4 percent of the adult population.

  • Risk factors

    Family history of psoriasis: supports the diagnosis when skin findings are ambiguous.

  • Pathophysiology

    Immune-mediated keratinocyte hyperproliferation: chronic, immune-driven accelerated epidermal turnover is the core process producing the thickened, scaling plaque.

  • Clinical features

    Plaque psoriasis, the diagnostic anchor: sharply marginated erythematous papules/plaques with thick, silvery-white (micaceous) scale and a crisp border, unlike the fuzzy fade-out of eczema.

  • Differential diagnosis

    Tinea corporis: clears centrally with an active, scaling leading edge, unlike the uniform, non-clearing plaque of psoriasis; potassium hydroxide preparation of the edge distinguishes the two.

  • Diagnosis

    Diagnosis is clinical: sharply demarcated plaques with silvery scale in the classic extensor/scalp distribution plus a positive Auspitz sign establish the diagnosis in typical cases; biopsy is reserved for atypical presentations.

  • Management

    First, classify severity by body surface area and site: mild-to-moderate localized disease is treated topically, while disease over 10 percent body surface area, recalcitrant disease, or disease at…

  • Complications

    Erythrodermic psoriasis: loss of heat, fluid, and electrolytes across a failing skin barrier, capable of driving high-output cardiac failure.

  • Prognosis

    Chronic, relapsing course: lifelong for most patients, though guttate psoriasis is often self-limited or converts to plaque disease within months.

  • Prevention

    Avoid systemic glucocorticoids and abrupt antipsoriatic drug withdrawal, the classic preventable trigger of erythrodermic and pustular flare.

Read the whole article

Subscribing to Internal Medicine opens every article, the full question bank and MedBrain, on the web, iPhone and Android.